jilibet hack Participation in the 9th World Oil and Gas Equipment Exhibition WOGE2024Special counsel moves to dismiss case against Trump

Democratic New York Rep. Jamaal Bowman has not figured out yet that Americans are fed up with the BLM-esque race-hustling that has sapped this country’s morale for the better of, I don’t know, four or five years. In June, Bowman suffered a crushing defeat in the Democratic primary for New York’s 16th Congressional district. The left-wing ‘Squad’ member, whose greatest achievement in Congress was pulling the fire alarm in a Capitol Hill office building, is still bitter about his constituents giving him the old boot, and now he wants to take out his frustration on white people. (Stream the Daily Caller’s ‘Demand For Hate’ documentary HERE) Bowman had a conniption for the ages Tuesday on X after a jury acquitted Daniel Penny of negligent homicide in the death of Jordan Neely. “Dear White People,” Bowman’s racist diatribe began. “I don’t know why I feel the need to keep talking to you. I don’t know why part of me still has hope for you and for us. Some of you are too far gone. But maybe enough of you aren’t and will join us in fighting to end white supremacy.” Dear White People, I don’t know why I feel the need to keep talking to you. I don’t know why part of me still has hope for you and for us. Some of you are too far gone. But maybe enough of you aren’t and will join us in fighting to end white supremacy. — Rep. Jamaal Bowman Ed.D. (@JamaalBowmanNY) December 10, 2024 Bowman went on to compare Neely’s death to Eric Garner’s, Trayvon Martin’s, George Floyd’s and Breonna Taylor’s, even though each case is so uniquely different. Then, he dropped the doozy. The two words everyone in this country is sick of hearing paired together: white and supremacy. “Black people are harmed or killed. And there is never accountability or justice. This is the evil of white supremacy. It spans across geography and political parties and sickens us all,” Bowman wrote before lamenting the “trauma” that resides “deep” in his bones. “I wish I didn’t have to live with all of this trauma deep in my bones. I wish I could just be free to be me. I marvel at the beauty and greatness of my people in spite of white supremacy. It’s extraordinary. That is what I will continue to lean on,” he concluded. Now that Bowman’s term in Congress is coming to an end, he will have plenty of time to ruminate on his deep trauma. He can pull all the fire alarms he wants, yell and express all the anger he wants, without feeling judgment, now that he is just an ordinary citizen, not an elected official. He’s finally free to be himself, but the only difference in 2025, compared to 2020, is that Americans no longer want to listen to race-baiters like him. Did you enjoy this post? Consider checking out John’s full weekly newsletter, Mr. Right, available here: MrRight.DailyCaller.comWalker has 22 as Binghamton knocks off Lancaster Bible 85-60

Jason Mackey: After strong start to season, Mike Tomlin deserves blame for Steelers' frustrating loss to BrownsArtificial intelligence (AI) continues to be one of the biggest driving forces in the stock market. While chipmakers and cloud computing companies have been the biggest early beneficiaries, software companies are starting to see nice growth opportunities emerge as well. That said, the semiconductor sector is still one of the best places to find attractively valued stocks tied to AI. Let's look at two semiconductor stocks that should see AI help power their growth in December and beyond. 1. Nvidia The biggest AI winner thus far has been Nvidia ( NVDA -1.81% ) , which has grown to become the second-largest company in the world. Nvidia originally developed a new type of semiconductor chip called a graphics processing unit (GPU) to help speed up the rendering of graphics in video games and elsewhere. For a long time, this was a niche industry dominated by Nvidia and ATI (which has since been acquired by Advanced Micro Devices ). Nvidia was able to expand the use of GPUs to other industries with the help of its CUDA software platform, which allowed the chips to be programmed to more efficiently handle tasks. This led to more developers learning to program GPUs using CUDA, which led to the developers purchasing Nvidia GPUs to do their work on, creating a virtuous circle and helping create the wide moat the company sees today. The use of GPUs in cryptocurrency mining became a growth driver for the company back in 2016-2017, but it was the use of GPUs for training large language models (LLMs) and AI inference in beginning in 2021-2022 that led to astronomical growth for Nvidia. Today, Nvidia's GPUs have become the backbone of the AI infrastructure buildout, and through the wide moat it gained with CUDA, it now holds an approximate 90% market share. Nvidia's CEO says the current demand for its chips is "insane," as the world's top tech companies race to become AI leaders. The biggest risk to the stock is if demand slows. However, Nvidia's largest customers have by and large expressed plans to continue ramping up AI infrastructure spending to take advantage of what many view as a once-in-a-generation opportunity. Also working in Nvidia's favor is that in order to improve their AI models, these companies need exponentially more computing power, and thus more GPUs, to train their models on. Despite its huge gains in the past few years, the stock trades at an attractive valuation. It has a forward price-to-earnings (P/E) ratio of about 33 based on 2025 analyst estimates, and a price/earnings-to-growth ( PEG ) ratio of approximately 1. A PEG ratio under 1 is usually considered undervalued, but growth stocks will often command PEG ratios well above 1. NVDA PE Ratio (Forward 1y) data by YCharts. All this makes Nvidia an attractive option to consider buying this month as we head into 2025. 2. Taiwan Semiconductor Manufacturing While Nvidia has become the dominant player in the GPU market, Taiwan Semiconductor Manufacturing ( TSM -0.63% ) , or TSMC for short, has become the leading player in the contract semiconductor manufacturing space. The company is a close partner with Nvidia and the primary manufacturer of its GPUs. Apple , meanwhile, is its largest customer, and the iPhone maker regularly buys out all of the capacity of TSMC's advanced nodes when TSMC moves to newer advanced chip manufacturing technology. TSMC thus has two big AI growth opportunities in front of it. The biggest remains making chips to meet the huge demand for AI chips coming from the AI infrastructure buildout. TSMC will continue to benefit from Nvidia's success, but it will also benefit from any companies looking to get in on this space as well. A number of companies have started to design custom AI chips through Broadcom and Marvell to meet specific needs, while Arm Holdings and Softbank have been rumored to be looking for manufacturing capacity to make their own AI chips. In addition to AI chips for data centers, TSMC would also benefit from any increased demand coming from an end device hardware upgrade cycle. Newer smartphones and PCs are generally needed to run the latest AI offerings, so any increased demand for smartphones or computers would benefit the company. Apple is pushing its new AI features with Apple Intelligence, which is expected to boost iPhone 16 sales, while Microsoft has been advancing its AI Copilot, which could help with an enterprise PC upgrade cycle. To meet growing demand, TSMC continues to invest in adding more capacity while also continuing to push technology innovation and shrinking node sizes. Smaller nodes allow for better chip performance and power consumption, while also increasing the number of chips that can fit on a wafer. TSMC has also displayed strong pricing power over the past few years, and it is set to raise prices once again in 2025. According to Morgan Stanley , the company will increase prices by 10% for CoWoS (chip on wafer on substrate), 6% for high-performance computing, and 3% for smartphones. Notably, CoWoS is a packaging technology used for high-performance chips, such as Nvidia's GPUs. Like Nvidia, TSMC trades at an attractive valuation, with a forward P/E under 23 based on analysts' 2025 estimates and a PEG of 1.2. TSM PE Ratio (Forward 1y) data by YCharts. Given the opportunity still in front of TSMC, it looks like a solid stock to buy in December ahead of what should be a strong 2025 for the company.

Idaho Legislature reveals committee chairpersons for upcoming legislative sessionNone

NPFL: Idahosa gifts Bendel Insurance N1.5m for win over Kwara United

Just what we need before Christmas – another berserk story from the Excited States of America showing how far the nation has slipped down the pole of insanity to irrelevance and anarchy. It all began a little more than a week ago when a young Ivy League school grad armed with a home-made “ghost gun” made from a 3D-printer got off his bicycle long enough in downtown Manhattan to stalk United Healthcare CEO Brian Thompson and put two bullets in the back of the former executive who fell to the cold concrete deader than the proverbial doornail. And few of the passers-by even looked up! The killer then hopped back on his bike and disappeared into the hazy air of a Manhattan morning and wasn’t caught until almost a week later when a sharp-eyed McDonalds’ customer came across him chowing down on a breakfast burger in Altoona, Pennsylvania and called the police who easily did what an army of cops couldn’t do in the biggest city in America. They arrested him on charges leading to murder. And now the stage is set for what is sure to become another “trial of the century” in a country losing its ability to separate right from wrong and in danger of losing its moral compass too. Will its highly polarized political class save it? Doubtful. Will its business billionaires and $500-an-hour lawyers do better? I doubt it even more. After all, they live off it and live obscenely well. Do I exaggerate? No way and point out that the person charged is one Luigi Mangione, 26, a former private school valedictorian, University of Pennsylvania graduate and son of Louis Mangione, a wealthy Baltimore businessman and resort owner. But Mangione’s wealth fades when compared to revenues of $371.6 billion made by UnitedHealthcare in 2023, making it the richest health care insurance provider in the USA. Murdered CEO Thompson was paid $100 million in salary alone the same year. But critics point out that United Healthcare regularly denies almost one-third of the claims made against it, strongly boosting its bottom line but leaving thousands of insurance claimants untreated. The evidence against Mangione is strong including bullet casings found at the scene matching his “ghost gun” and imprinted with “Delay, deny, defend” a phrase he borrowed from the “Unabomber” Ted Kaczynski, who he greatly admired. In a bizarre manifesto, alleged to be written by Mangione, he showed his hatred of the American health care system after unsuccessful back surgery. “Frankly, these parasites simply had it coming,” he said, adding Americans pay the highest health care rates in the world but get results below some Third World countries. He also praised the anti-technology theories of Indian philosopher Jiddu Krishnamurti who accused Americans of becoming “well-adjusted to a profoundly sick society.” Despite his fanatic views, Mangione has won support from thousands, possibly millions, of Americans, who clearly support his extreme views and hatred of the American health care system. “Free Luigi” memes are all over the Internet and other social media platforms and there’s wide-spread speculation over who should play the manly looking killer if a movie is made of his infamous exploits. But this hasn’t impressed Pennsylvania Governor Josh Shapiro according to a story on PBS. “In some dark corners, this killer is being hailed as a hero. Hear me on this, he is no hero,” Shapiro said. “The real hero in this story is the person who called 911 at McDonald’s this morning.” But a wave of derogatory posts quickly swept over the Net supporting Mangione’s despicable deed. Being a Canadian, I dislike writing so often about the craziness of American politics. But what can you do? There’s no other county in the world that resembles Uncle Sam as much as the Great White North and we’re not exactly enamored with our health care system either. But to gun someone down on the street in cold blood doesn’t make sense. It only makes the situation worse and encourages more violence of the most abhorrent kind. Don’t you agree? is a retired journalist, who doesn’t know what to think anymore.THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: Adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-ALL during the consolidation phase of multiphase therapy. CD19-positive B-ALL in first or second complete remission with MRD greater than or equal to 0.1% in adults and pediatric patients one month or older. Relapsed or refractory CD19-positive B-ALL in adults and pediatric patients one month or older. In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: Adults with Philadelphia chromosome-negative CD19-positive relapsed or refractory B-ALL. Patients with Philadelphia chromosome-positive B-ALL should have failed treatment with at least two tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. Adults with Philadelphia chromosome-negative CD19-positive B-ALL in first or second complete remission with MRD greater than or equal to 0.1%. Pediatric patients aged 1 year or older with Philadelphia chromosome-negative CD19-positive B-ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. Pediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome-negative CD19-positive B-ALL as part of the consolidation therapy. BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO ® . Interrupt or discontinue BLINCYTO ® and treat with corticosteroids as recommended. Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO ® . Interrupt or discontinue BLINCYTO ® as recommended. Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Cytokine Release Syndrome (CRS): CRS, which may be life-threatening or fatal, occurred in patients receiving BLINCYTO ® . The median time to onset of CRS is 2 days after the start of infusion and the median time to resolution of CRS was 5 days among cases that resolved. Closely monitor and advise patients to contact their healthcare professional for signs and symptoms of serious adverse events such as fever, headache, nausea, asthenia, hypotension, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased total bilirubin (TBILI), and disseminated intravascular coagulation (DIC). The manifestations of CRS after treatment with BLINCYTO ® overlap with those of infusion reactions, capillary leak syndrome (CLS), and hemophagocytic histiocytosis/macrophage activation syndrome (MAS). Using all of these terms to define CRS in clinical trials of BLINCYTO ® , CRS was reported in 15% of patients with R/R ALL, in 7% of patients with MRD-positive ALL, and in 16% of patients receiving BLINCYTO ® cycles in the consolidation phase of therapy. If severe CRS occurs, interrupt BLINCYTO ® until CRS resolves. Discontinue BLINCYTO ® permanently if life-threatening CRS occurs. Administer corticosteroids for severe or life-threatening CRS. Neurological Toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome: BLINCYTO ® can cause serious or life-threatening neurologic toxicity, including ICANS. The incidence of neurologic toxicities in clinical trials was approximately 65%. The median time to the first event was within the first 2 weeks of BLINCYTO ® treatment. The most common (≥ 10%) manifestations of neurological toxicity were headache and tremor. Grade 3 or higher neurological toxicities occurred in approximately 13% of patients, including encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders. Manifestations of neurological toxicity included cranial nerve disorders. The majority of neurologic toxicities resolved following interruption of BLINCYTO ® , but some resulted in treatment discontinuation. The incidence of signs and symptoms consistent with ICANS in clinical trials was 7.5%. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. There is limited experience with BLINCYTO ® in patients with active ALL in the central nervous system (CNS) or a history of neurologic events. Patients with a history or presence of clinically relevant CNS pathology were excluded from clinical studies. Patients with Down Syndrome over the age of 10 years may have a higher risk of seizures with BLINCYTO ® therapy. Monitor patients for signs and symptoms of neurological toxicities, including ICANS, and interrupt or discontinue BLINCYTO ® as outlined in the PI. Advise outpatients to contact their healthcare professional if they develop signs or symptoms of neurological toxicities. Infections: Approximately 25% of patients receiving BLINCYTO ® in clinical trials experienced serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections, some of which were life-threatening or fatal. Administer prophylactic antibiotics and employ surveillance testing as appropriate during treatment. Monitor patients for signs or symptoms of infection and treat appropriately, including interruption or discontinuation of BLINCYTO ® as needed. Tumor Lysis Syndrome (TLS), which may be life-threatening or fatal, has been observed. Preventive measures, including pretreatment nontoxic cytoreduction and on-treatment hydration, should be used during BLINCYTO ® treatment. Monitor patients for signs and symptoms of TLS and interrupt or discontinue BLINCYTO ® as needed to manage these events. Neutropenia and Febrile Neutropenia, including life-threatening cases, have been observed. Monitor appropriate laboratory parameters (including, but not limited to, white blood cell count and absolute neutrophil count) during BLINCYTO ® infusion and interrupt BLINCYTO ® if prolonged neutropenia occurs. Effects on Ability to Drive and Use Machines: Due to the possibility of neurological events, including seizures and ICANS, patients receiving BLINCYTO ® are at risk for loss of consciousness, and should be advised against driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO ® is being administered. Elevated Liver Enzymes: Transient elevations in liver enzymes have been associated with BLINCYTO ® treatment with a median time to onset of 3 days. In patients receiving BLINCYTO ® , although the majority of these events were observed in the setting of CRS, some cases of elevated liver enzymes were observed outside the setting of CRS, with a median time to onset of 19 days. Grade 3 or greater elevations in liver enzymes occurred in approximately 7% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients. Monitor ALT, AST, gamma-glutamyl transferase, and total blood bilirubin prior to the start of and during BLINCYTO ® treatment. BLINCYTO ® treatment should be interrupted if transaminases rise to > 5 times the upper limit of normal (ULN) or if total bilirubin rises to > 3 times ULN. Pancreatitis: Fatal pancreatitis has been reported in patients receiving BLINCYTO ® in combination with dexamethasone in clinical trials and the post-marketing setting. Evaluate patients who develop signs and symptoms of pancreatitis and interrupt or discontinue BLINCYTO ® and dexamethasone as needed. Leukoencephalopathy: Although the clinical significance is unknown, cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO ® , especially in patients previously treated with cranial irradiation and antileukemic chemotherapy. Preparation and administration errors have occurred with BLINCYTO ® treatment. Follow instructions for preparation (including admixing) and administration in the PI strictly to minimize medication errors (including underdose and overdose). Immunization: Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of BLINCYTO ® treatment, during treatment, and until immune recovery following last cycle of BLINCYTO ® . Benzyl Alcohol Toxicity in Neonates: Serious adverse reactions, including fatal reactions and the "gasping syndrome," have been reported in very low birth weight (VLBW) neonates born weighing less than 1500 g, and early preterm neonates (infants born less than 34 weeks gestational age) who received intravenous drugs containing benzyl alcohol as a preservative. Early preterm VLBW neonates may be more likely to develop these reactions, because they may be less able to metabolize benzyl alcohol. Use the preservative-free preparations of BLINCYTO ® where possible in neonates. When prescribing BLINCYTO ® (with preservative) for neonatal patients, consider the combined daily metabolic load of benzyl alcohol from all sources including BLINCYTO ® (with preservative), other products containing benzyl alcohol or other excipients (e.g., ethanol, propylene glycol) which compete with benzyl alcohol for the same metabolic pathway. Monitor neonatal patients receiving BLINCYTO ® (with preservative) for new or worsening metabolic acidosis. The minimum amount of benzyl alcohol at which serious adverse reactions may occur in neonates is not known. The BLINCYTO ® 7-Day bag (with preservative) contains 7.4 mg of benzyl alcohol per mL. Embryo-Fetal Toxicity: Based on its mechanism of action, BLINCYTO ® may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with BLINCYTO ® and for 48 hours after the last dose. Adverse Reactions The safety of BLINCYTO ® in adult and pediatric patients one month and older with MRD-positive B-cell precursor ALL (n=137), relapsed or refractory B-cell precursor ALL (n=267), and Philadelphia chromosome-negative B-cell precursor ALL in consolidation (n=165) was evaluated in clinical studies. The most common adverse reactions (≥ 20%) to BLINCYTO ® in this pooled population were pyrexia, infusion-related reactions, headache, infection, musculoskeletal pain, neutropenia, nausea, anemia, thrombocytopenia, and diarrhea. Dosage and Administration Guidelines BLINCYTO ® is administered as a continuous intravenous infusion at a constant flow rate using an infusion pump which should be programmable, lockable, non-elastomeric, and have an alarm. It is very important that the instructions for preparation (including admixing) and administration provided in the full Prescribing Information are strictly followed to minimize medication errors (including underdose and overdose). INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Philadelphia chromosome-negative disease in the consolidation phase of multiphase chemotherapy. Minimal residual disease (MRD) greater than or equal to 0.1% in first or second complete remission. Relapsed or refractory disease. Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References National Institute of Health. Cancer Stat Facts: Leukemia — Acute Lymphocytic Leukemia (ALL). Available at: https://seer.cancer.gov/statfacts/html/alyl.html . Accessed on October 28, 2024 . Terwilliger T, et al. Blood Cancer J . 2017;7(6):e577. American Cancer Society. What is Acute Lymphocytic Leukemia (ALL)? Available at: https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/about/what-is-all.html . Accessed on October 28, 2024 . Leukemia & Lymphoma Society. Acute Lymphoblastic Leukemia (ALL). Available at: https://www.lls.org/research/acute-lymphoblastic-leukemia-all . Accessed on October 28, 2024 . National Cancer Institute. Childhood Acute Lymphoblastic Leukemia (PDQ ® )–Patient Version. Available at: https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq . Accessed on November 19, 2024 . View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenFORT WORTH, Texas (AP) — Navy quarterback Blake Horvath read the play perfectly and turned it into the longest in school history, a 95-yard touchdown run in the Armed Forces Bowl. “By somebody that’s not really that fast,” Horvath said after the 21-20 win over Oklahoma on Friday. The Midshipmen (10-3) fell behind by two touchdowns less than 10 minutes into the game, but Horvath's record run late in the third quarter tied the game at 14-all. He put them ahead on a 6-yard TD with 4:34 left before Navy’s defense stopped an Oklahoma 2-point conversion with six seconds left in the game. “Probably over-pursued by them,” Horvath said of the 95-yarder. “Some tendencies they showed earlier, just thought I could get a pull.” After faking a handoff on the read-option play, Horvath ran straight up the middle into the open field. Brandon Chatman cut off a pursing defender around the Sooners 20. By time another defender, cornerback Woodi Washington, was able to catch up and started to bring him down, Horvath stretched the ball over the goal line — though he was initially ruled short before a replay review resulted in the touchdown. “Brandon Chatman actually busted his tail to get his butt down the field,” Horvath said. “I can see him out of the corner of my eye busting his butt. And honestly, it’s almost not even my touchdown without him and the offensive line blocking.” The previous longest play for the Midshipmen came during the Roger Staubach era, when Johnny Sai had a 93-yard run against Duke in 1963. Horvath also had a 90-yard TD run against Memphis, making him only the second Navy player with two 90-yard runs in the same season. The other was quarterback Malcolm Perry in 2017, when he had runs of 92 and 91 yards. “That’s a play we know can hit big and it did, and definitely exciting to see,” fullback Alex Tecza said. “I was getting tired just chasing him. ... It's great. He's being doing that all year.”

SHE is the female star who features in four of the most-successful movies of all time. But besides the success of her work in the Avatar and Avengers movies, Zoe Saldaña is embracing the opportunity to return to her Spanish-language roots in Emilia Pérez. Saldaña acts, sings and even raps in Spanish in the movie, which is her first major role in the language she grew up with. Against a backdrop of original songs and dance, Emilia Pérez tells the stories of four women in Mexico. A powerful cartel leader enlists lawyer Rita (Saldaña) to help fake their death and transition into living as a woman, Emilia. The lead actress Karla Sofía Gascón’s own transition helped inform the film, from French director Jacques Audiard (A Prophet). The result is a once-in-a-lifetime role for Saldaña, who has become a favourite to pick up the Oscar for Best Supporting Actress next spring. The actress grew up in the US, but working in Spanish gave her the opportunity to embrace her Dominican and Puerto Rican roots. “I feel like the first stories I heard as a baby, as a child, the first songs I heard, my mother singing to me, my grandmother, it was in my native tongue. “But I'm also very American. I've always lived in the lines between these both worlds, my old world and my new world. Being a first generation, you code-switch a lot. That was my world, and that was the world around me growing up in New York as being one among so many children of immigrants. There was always that desire to reconnect with my language, because I really do. I love art in Spanish. I love reading in Spanish, listening to music.” The role also gave Saldaña the chance to revisit the career she originally dreamed of - dance. A trained dancer, she gets to show skills first honed decades earlier in one epic scene in the movie. “It was great that I was still able to do it,” she says. “Your body's an extraordinary organism. The moment you stop pushing it in one direction, it immediately decides to go in another. The last time I had danced was 20 years ago. I've done stunts, and I always stay sort of active and athletic but dance was always my first love, and it wasn't meant to be. I didn't have the feet, and that was a very heartbreaking thing for me to know that no matter how much I was going to push, I was never going to get there. “Transitioning into acting was the next thing I could do,” she says, adding that being given the opportunity two decades later was exciting but also daunting. “This opportunity, I couldn't pass it. I was going to rehearse it until my bones were out, and get it in my own way. “It started out where I was really insecure and feeling really rusty, and then by the time we started shooting the movie, after six, seven weeks of rehearsals, I couldn't wait to start shooting. I just felt like I was equipped to deliver a good service. I was like: this is my one chance, I'm in my mid 40s, and I'm doing something like this. I was invigorated. I was so energised, repurposed, reconnected.” Writer and director Jacques Audiard has always been a rebel when it came to his screen stories. Having made his breakthrough with 2009 French drama thriller A Prophet, chronicling a young criminal’s gradual rise to the very top of the mob’s ranks, the filmmaker is not one for doing the same thing twice. In the years since, he has brought audiences the Marion Cotillard-starring drama Rust and Bone and his own take on the classic Western, The Sisters Brothers. Emilia Pérez goes to the next level, bringing us a character transitioning in the world of Mexican narcos in a fever-dream genre-buster that includes melodrama and a few musical numbers. It should come as no surprise that the maverick filmmaker was a big collaborator with his cast. “A lot of the story was on the page, but a lot of it was more through Jacques telling us what this was going to be, because it was an ongoing writing that he kept doing the moment he casted, and everybody sort of had the freedom to to flesh out their characters,” says Saldaña. “It was a very collaborative experience in terms of how we were putting our characters together, knowing the bare bones of each character, and knowing the bare bones of the story, it still felt like an extremely collaborative experience with Jacques. Working with him was like an experience and an experiment, because you knew where you were going, and yet you expected to be pleasantly surprised every day.” Since she kick-started her acting career with appearances in TV series Law & Order, Saldaña has quietly become one of Hollywood’s most-successful stars. She holds the distinction of appearing in four of the highest-grossing movies of all time: Avatar, Avatar: The Way of Water, Avengers: Infinity War and Avengers: Endgame. Regardless of how intimate or epic the project, the actress says that finding the right people to work has always been crucial to her. “I've been fortunate. I feel like I've worked with extremely collaborative directors,” she says. “I've also worked with directors that are very specific, and that also develops a different form of trust, because you know exactly what they want, and there's no figuring things out. Your job is to make sure that you come prepared with all the tools they've given you, and just be ready on set to do it. I'm okay with that as well. “I just enjoy a process where the filmmaker is confident in what they wrote and confident in how you're going to affect it for the better. And there's that collaboration, because I'm an extremely vocal and open person and a very passionate individual, so I just feel very accepted when somebody understands my language and they allow me to participate a little more in their project. It just feels really good - and Jacques was that person.” Five films to watch out for Wicked, cinemas from November 22: A young woman named Elphaba forges an unlikely friendship with Glinda in Part One of the highly anticipated musical adaptation. Reviews have been mixed, but many fans still won't resist going along to see it. Blitz, Apple TV from November 22: Saoirse Ronan stars in Steve McQueen’s new drama, set in Wartime London during the bombings. The Magic Reindeer: Saving Santa’s Sleigh, cinemas from November 22: A young Niko’s latest animated adventures in this festive third film in the series. Housewife of the Year, cinemas from November 22: Former contestants in the Housewife of the Year competition speak of social change and resilience in this Irish documentary. Point Break, Triskel, November 24-27: Director Kathryn Bigelow’s much-loved 1991 action drama, starring Keanu Reeves and Patrick Swayze, returns to the screen.

When Katja Vogt considers a Jaguar, she pictures a British-made car purring confidently along the Italian coastline — a vision of familiarity that conveys "that dreaming, longing feeling we all love." She's not sure what to think about Jaguar now after the 89-year-old company announced a radical rebranding that featured loud colors and androgynous people — but no cars. Jaguar, the company says, will now be JaGUar. It will produce only electric vehicles beginning in 2026. Bad attention is good attention, Jaguar execs would appear to believe. The car brand has prompted mockery online for posting a glitzy ad without a single car in it. Say goodbye to British racing green, Cotswold Blue and black. Its colors are henceforth electric pink, red and yellow, according to a video that sparked backlash online. Its mission statement: "Create exuberance. Live vivid. Delete ordinary. Break moulds." "Intrigued?" @Jaguar posted on social media. "Weird and unsettled" is more like it, Vogt wrote on Instagram. "Especially now, with the world feeling so dystopian," the Cyprus-based brand designer wrote, "a heritage brand like Jaguar should be conveying feelings of safety, stability, and maybe a hint of rebellion — the kind that shakes things up in a good way, not in a way that unsettles." Our brands, ourselves Jaguar was one of several iconic companies that announced significant rebrandings in recent weeks, upending a series of commercial — and cultural — landmarks by which many modern human beings sort one another, carve out identities and recognize the world around them. Campbell's, the 155-year-old American icon that artist Andy Warhol immortalized in pop culture decades ago, is ready for a new, soupless name. Comcast's corporate reorganization means there will soon be two television networks with "NBC" in their name — CNBC and MSNBC — that will no longer have any corporate connection to NBC News, a U.S. legacy news outlet. CNBC One could even argue the United States itself is rebranding with the election of former President Donald Trump and Republican majorities in the House and Senate. Unlike Trump's first election in 2016, he won the popular vote in what many called a national referendum on American identity. Are we, then, the sum total of our consumer decisions — what we buy, where we travel and whom we elect? Certainly, it's a question for those privileged enough to be able to afford such choices. Volumes of research in the art and science of branding — from "brandr," an old Norse word for burning symbols into the hides of livestock — say those factors do contribute to the modern sense of identity. So rebranding, especially of heritage names, can be a deeply felt affront to consumers. "It can feel like the brand is turning its back on everything that it stood for — and therefore it feels like it's turning its back on us, the people who subscribe to that idea or ideology," said Ali Marmaduke, strategy director with the Amsterdam-based Brand Potential. He said cultural tension — polarization — is surging over politics, wars in Russia and the Mideast, the environment, public health and more, creating what Marmaduke said is known as a "polycrisis": the idea that there are several massive crises converging that feel scary and complex. Campbell's soups "People are understandably freaked out by that," he said. "So we are looking for something that will help us navigate this changing, threatening world that we face." Trump's "Make America Great Again" qualifies. So did President Joe Biden's "Build Back Better" slogan. Campbell's soup itself — "Mmm Mmm Good" — isn't going anywhere, CEO Mark Clouse said. The company's new name, Campbell's Co., will reflect "the full breadth of our portfolio," which includes brands like Prego pasta sauce and Goldfish crackers. What is Jaguar? None of the recent activity around heritage brands sparked a backlash as ferocious as Jaguar's. The company stood as a pillar of tradition-loving British identity since World War II. The famous "leaper" cat Jaguar logo is pictured in 2019 at the Auto show in Paris, France. Jaguar said its approach to the rebrand was rooted in the philosophy of its founder, Sir William Lyons, to "copy nothing." What it's calling "the new Jaguar" will overhaul everything from the font of its name to the positioning of it's famous "leaper" cat. "Exuberant modernism" will "define all aspects of the new Jaguar world," according to the news release. The approach is thought to be aimed at selling fewer cars at a six-figure price point to a more diverse customer base. The reaction ranged from bewilderment to hostility. Memes sprouted up likening the video to the Teletubbies, a Benetton ad and — perhaps predictably — a bow to "woke" culture as the blowback intersected with politics. The business news you need Get the latest local business news delivered FREE to your inbox weekly.

Overhauls of 'heritage brands' raise the question: How important are our products to our identities?